T2 Biosystems Inc represents a set of core values and a corporate philosophy that drives its operations. The company focuses on innovation, leveraging cutting-edge technology to revolutionize diagnostics. T2 Biosystems Inc is committed to improving patient outcomes by providing faster and more accurate diagnostic solutions. With a strong emphasis on collaboration, T2 Biosystems Inc actively engages with healthcare professionals and partners to develop impactful solutions. The company's dedication to excellence, integrity, and efficiency reflects its commitment to delivering value to patients, healthcare providers, and stakeholders. T2 Biosystems Inc continually strives to advance healthcare through breakthrough innovations and a patient-centric approach.

T2 Biosystems Inc is primarily present in the United States and Europe.

T2 Biosystems Inc, a leading biotechnology company, has achieved several significant milestones. Firstly, the company developed and received FDA clearance for the T2Dx® Instrument, allowing rapid and accurate identification of deadly pathogens directly from whole blood. Furthermore, T2 Biosystems successfully launched their T2Bacteria® and T2Candida® Panels, revolutionizing the diagnosis of bloodstream infections. Additionally, the company secured numerous strategic partnerships and collaborations to expand the reach of their innovative technologies. With these achievements, T2 Biosystems Inc continues to make remarkable progress in improving patient outcomes by providing faster and more precise diagnostic solutions.

T2 Biosystems Inc is a leading diagnostic company specializing in the development and commercialization of innovative technologies. Founded in 2006, T2 Biosystems has been revolutionizing the medical industry by providing rapid and accurate diagnostic solutions. The company focuses on the detection of pathogens and other critical conditions, aiming to improve patient outcomes and save lives. With its unique T2 Magnetic Resonance (T2MR) technology, T2 Biosystems has gained recognition as a pioneer in the field of diagnostics. T2 Biosystems Inc continues to drive advancements in diagnostic testing and is committed to delivering reliable results for healthcare professionals globally.

The main competitors of T2 Biosystems Inc in the market are bioMérieux SA, Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, and Bruker Corporation.

T2 Biosystems Inc is primarily active in the healthcare and medical technology industries.

The business model of T2 Biosystems Inc is centered around developing and commercializing innovative medical diagnostic products. The company focuses on creating breakthrough solutions for the detection of severe infections, such as bloodstream infections, that can lead to life-threatening conditions. T2 Biosystems utilizes its proprietary T2 Magnetic Resonance (T2MR®) technology, which enables rapid and accurate detection of pathogens directly from a patient's whole blood sample. This technology eliminates the need for time-consuming culture-based methods, offering healthcare providers timely and actionable results. By applying cutting-edge molecular diagnostics to improve patient outcomes, T2 Biosystems Inc has established itself as a leader in the field of infectious disease diagnostics.

T2 Biosystems의 P/E 비율은 -0.09입니다.

T2 Biosystems의 P/S 비율은 0.44입니다.

T2 Biosystems에 대한 AlleAktien 품질 점수는 8/10입니다.

예상되는 T2 Biosystems 매출은 10.81 백만 USD입니다.

예상되는 T2 Biosystems 이익은 -55.27 백만 USD입니다.

T2 Biosystems Inc. is a biotechnology company specializing in the development and commercialization of diagnostic solutions. The company is based in Lexington, Massachusetts, USA, and offers a comprehensive portfolio of products and services. T2 Biosystems' business model is focused on three main areas: diagnostics, research and development, and clinical trials. The company aims to improve and expedite diagnostics in the areas of infectious diseases and sepsis. The flagship product of T2 Biosystems is the T2 Magnetic Resonance (T2MR) technology, an innovative method for rapid and accurate diagnosis of infections. This approach uses magnetic resonance technologies to detect pathogens directly in blood samples. Unlike traditional tests, T2MR technology can identify infections in less than six hours, leading to faster and more targeted treatment. Other products of T2 Biosystems include T2Candida, a blood test for the diagnosis of Candida infections, and T2Bacteria, a blood test for the diagnosis of bacterial infections. The company is also working on developing tests for detecting antibiotic resistance in infections. In the research and development field, T2 Biosystems continuously invests in improving its technologies and products. The company collaborates with universities, research institutions, and other companies to accelerate its research processes and achieve optimal results. This includes collaborations with the Centers for Disease Control and Prevention (CDC) and the United States Department of Defense (DoD). Clinical trials are another focus of T2 Biosystems. The company works with physicians and medical facilities to test and validate its diagnostic products in clinical settings. By collaborating with these institutions, the company gains a better understanding of the clinical effectiveness of its products and technologies and receives feedback from medical professionals. T2 Biosystems sells its products and solutions worldwide through a network of distribution partners and customers. The company also collaborates with hospitals and clinical laboratories to directly sell its technologies and products to healthcare professionals. Overall, T2 Biosystems' business model aims to revolutionize diagnostics in the field of infections. Through the development of innovative diagnostic technologies and collaboration with medical professionals, the company aims to achieve faster, more accurate, and more effective diagnostics, leading to improved patient care.

T2 Biosystems은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

T2 Biosystems의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

T2 Biosystems의 ISIN은 US89853L1044입니다.

T2 Biosystems의 WKN은 A119H3입니다.

T2 Biosystems의 티커는 TTOO입니다.

지난 12개월 동안 T2 Biosystems은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 T2 Biosystems은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

T2 Biosystems의 현재 배당 수익률은 입니다.

T2 Biosystems은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

T2 Biosystems은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

T2 Biosystems은 '건강' 섹터에 속합니다.

T2 Biosystems의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 T2 Biosystems는 0 USD를 배당금으로 지급했습니다.

T2 Biosystems의 배당금은 USD에 지급됩니다.